WuXi Vaccines to build $240m facility in Ireland

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Photo world)
(Image: Getty/Photo world)

Related tags: Wuxi biologics, WuXi Vaccines, Ireland

WuXi Biologics furthers its manufacturing presence in Ireland with a manufacturing facility for its vaccines subsidiary, which will be able to produce both drug substance and drug product.

WuXi Biologics had previously chosen County Louth, Ireland, to be the home of its first manufacturing site outside of China, with a €325m ($357m) single-use facility​.

The Chinese company has continued to utilize Ireland as a hub outside of China by announcing that its subsidiary, WuXi Vaccines, will invest $240m in the construction of a manufacturing facility, located within the WuXi Biologics Campus in Dundalk.

Once completed, the facility will create 200 jobs in the region, adding to the 400 jobs already created by the single-use facility.

The vaccine facility will be able to produce drug substance and drug product, as well as possessing quality control labs, to produce vaccine product for an unnamed ‘large global pharma’ for the global market.

At the time of the creation of WuXi Vaccines, the company announced that it had signed a 20-year manufacturing contract​ with the unnamed company. The value of the contract itself was stated to be $3bn, allowing WuXi Vaccines to invest heavily in the manufacturing facility in the knowledge that it had guaranteed revenue.

The product that is set to be manufactured is currently undergoing clinical trials, with CEO of WuXi Biologics, Chris Chen, only telling BioPharma-Reporter, at the time, that the drug candidate would be a ‘first of its kind’ in the industry.

Chen added further that the vaccine contract development and organization (CDMO) business will be a future growth area for the company.

In first half financial results for 2019​, WuXi Biologics was already able to point to strong growth in revenue, of 52.4%, with profit rising by 61.8%, to $94.9m, during this period.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers